How Research Peptides Are Made: From Solid-Phase Synthesis to the Sealed Vial

Research peptides are made by solid-phase peptide synthesis (SPPS): the chain is built one protected amino acid at a time on insoluble resin beads, cut from the resin and deprotected with trifluoroacetic acid (TFA), purified by preparative reversed-phase HPLC, often exchanged from the trifluoroacetate to the acetate salt, then freeze-dried, filled into vials and sealed. Each stage can leave a by-product with a mass that can be calculated in advance, and those by-products are what the HPLC purity line and the mass-spectrometry identity line on an analytical report are there to catch. The research peptides reference covers what the material is; this page covers how it is made, which listed compounds carry the harder structural features, and the impurity masses each one can show. Pepta Labs is a reseller, not a manufacturer: none of these stages takes place at Pepta Labs.

What are the stages between an amino-acid sequence and a sealed vial?

A research peptide passes through six stages between its written sequence and a sealed vial: chain assembly, cleavage, preparative purification, salt exchange, freeze-drying and filling. The route below is the common Fmoc route used for most commercial synthetic peptides; the production records of a given source are not part of a Pepta Labs report.

How does solid-phase peptide synthesis build the chain, and which impurities can it leave?

Solid-phase peptide synthesis builds a peptide from its C-terminus to its N-terminus while the growing chain stays bound to a resin bead, so excess reagents are simply washed away after each step. Each cycle has three parts: a mild base (usually piperidine) removes the Fmoc group that blocks the chain's free amine; a coupling reagent converts the next amino acid's carboxyl group into a reactive ester, which forms the new peptide bond; and the resin is washed. Side chains stay protected throughout, most often as tert-butyl (Ser, Thr, Tyr, Asp, Glu), trityl (Asn, Gln, His, Cys), Boc (Lys, Trp) and Pbf (Arg). The resin also fixes the C-terminus: an amide resin gives a C-terminal amide (-NH2), an acid resin a free acid (-OH).

A chain of n residues needs n−1 couplings, and incompleteness compounds. As illustrative arithmetic, not a record of any production run: at 99.0% completeness per coupling, the share of chains with no missing residue is 98.0% for a 3-residue chain such as KPV, 86.9% for the 15 residues of BPC-157, 65.6% for the 43 residues of TB-500 and 63.6% for the 46 residues of FOXO4-DRI. That is why long chains leave more material for the purification stage to remove.

• Deletion sequences: one residue missing after an incomplete coupling; the mass falls by that residue's mass, for example −57.02 Da for Gly or −97.05 Da for Pro.
• Truncated sequences: chains that stopped early. If unreacted chains are capped with acetic anhydride, the short chain carries an acetyl group (+42.01 Da on the shorter sequence).
• Epimers: one residue inverted from L to D (or D to L) during coupling, most often at His or Cys. The mass is unchanged (0 Da).
• Aspartimide: the Asp side chain closes onto the next backbone nitrogen under repeated base exposure, losing water (−18.01 Da). The ring can reopen as the β-aspartyl isomer (0 Da) or pick up piperidine (+67.08 Da). Asp-Gly is the most prone motif; Asp-Asn, Asp-Ser and Asp-Thr follow.

Report consequence: deletion, truncated and aspartimide species usually elute as separate minor peaks, which lowers the HPLC area-% figure, and each has a mass that differs from the target. Epimers and β-aspartyl isomers have exactly the target mass, so only the chromatography can separate them. The HPLC purity guide explains how the minor peaks are integrated.

What happens at cleavage, and where does trifluoroacetate come from?

Cleavage is the step in which a mixture of about 95% trifluoroacetic acid with scavengers cuts the finished chain from the resin and removes the side-chain protecting groups in the same operation. The protecting groups leave as reactive carbocations; the scavengers trap them before they can attach to electron-rich side chains such as Trp, Met, Tyr and Cys. The crude peptide is then precipitated and dried.

Trifluoroacetate enters the product here. In strong acid every basic site on the peptide (a free N-terminal amine and each Lys, Arg and His side chain) is protonated and pairs with a trifluoroacetate anion (CF₃COO⁻, 113.02 g/mol). Preparative HPLC normally uses about 0.1% TFA in the mobile phase as well, so a peptide that is not exchanged afterwards reaches the vial as a trifluoroacetate salt.

Report consequence: a protecting group left in place adds its mass: +56.06 Da for tert-butyl, +100.05 Da for Boc, +242.11 Da for trityl or +252.08 Da for Pbf. These species are more hydrophobic and elute after the main peak. A Met sulfoxide or an oxidized Trp formed during cleavage adds +15.99 Da and usually elutes just before it. The counter-ion does not appear in the mass spectrum; it dissociates on ionization.

How is the crude peptide purified and exchanged to acetate?

Preparative reversed-phase HPLC is the purification step: the crude peptide is loaded onto a wide C18 column and eluted with a rising acetonitrile gradient, and the eluate is collected as a series of fractions. In the common route each fraction is checked by analytical HPLC and mass spectrometry, and only the fractions that meet the target purity are pooled. The sample load, the gradient and the fraction cut decide how much of each impurity reaches the pooled material.

Salt exchange is a separate manufacturer step that replaces trifluoroacetate with acetate (CH₃COO⁻, 59.04 g/mol) or chloride. It is done by passing the peptide over an ion-exchange resin loaded with the new counter-ion, by a second preparative run with an acetate-containing mobile phase, or by repeated freeze-drying from dilute acid. The sequence, formula and mass of the peptide do not change; only the counter-ion does. Because each basic site carries one counter-ion, a heavily basic chain gains the most mass from its salt: FOXO4-DRI (listing) has ten Arg and four Lys residues. The TFA vs acetate guide works through that arithmetic and lists the salt form recorded for each listed compound.

Report consequence: the HPLC purity figure describes the pooled fractions, and the salt-form wording on a listing (the Pepta Labs compound records give most peptides as typically supplied as an acetate or trifluoroacetate salt) describes the counter-ion, not purity. Counter-ion and water content are separate assays; how net peptide content is determined covers them.

How is the purified peptide freeze-dried, filled and sealed?

Freeze-drying (lyophilization) turns the pooled peptide solution into a dry solid in three steps: the solution is frozen; under vacuum the ice sublimes directly to vapour (primary drying); and a warmer, longer hold removes most of the water still bound to the solid (secondary drying). Volatile acid leaves with the water, and the peptide remains as a porous white or off-white cake or powder; GHK-Cu, a copper complex, is blue. Filling follows one of two routes: the solution is dispensed into vials and freeze-dried in them, or the peptide is freeze-dried in bulk and the powder is weighed into vials. The vials are then closed and sealed.

Report consequence: the quantity on a Pepta Labs label is a supplier-stated nominal quantity in mg, and vial fill quantity is not independently measured. "Vial labels identify the compound, quantity and research-use designation. They do not carry lot or batch numbers." The gross mass in a vial includes counter-ion and residual water as well as peptide.

Which listed compounds carry structural features that are harder to make?

A listed peptide needs extra synthesis steps when it has a long chain, D- or non-coded residues, a modified terminus, a ring or bridge, or a metal. The table below is built from the verified sequences in the Pepta Labs compound records, longest chain first; notation such as Ac-, -NH2, pGlu and D- is explained in the sequence notation guide.

Three patterns stand out. Six compounds carry designed D-residues (FOXO4-DRI, Ipamorelin, SS-31, Melanotan-I, Melanotan-II and PT-141). Two are rings closed by a side-chain lactam (Melanotan-II and PT-141) and one by a disulfide (AOD-9604, covered in the AOD-9604 guide). SS-31, discussed in the SS-31 guide, is only four residues long but uses two building blocks outside the standard set. NAD+ and 5-Amino-1MQ are not peptides and are not made by SPPS. Listings whose identity record is not yet verified on the site are left out of this table and the next.

Which impurity masses can each listed compound show on a report?

Each listed peptide can show a predictable set of impurity masses, set by its own residues: +15.99 Da for each oxidized Met or Trp, −18.01 Da for an aspartimide at an Asp, +0.98 Da for a deamidated Asn, and a loss equal to any group added by design. The table gives the calculated monoisotopic mass of each compound's recorded formula and, for each sequence-specific species, the shift and the resulting mass. All values are calculated with monoisotopic atomic masses (C 12.000000, H 1.007825, N 14.003074, O 15.994915, S 31.972071, Cu 62.929599), not measured.

Three findings follow from the table. None of the verified sequences contains Asp-Gly, the motif most prone to aspartimide, or Asp-Ser; the only motifs from that ranking that appear are Asp-Asn in VIP (Asp-8/Asn-9) and Asp-Thr in Thymosin Alpha-1 (Asp-6/Thr-7). The only Asn-Gly pair is in FOXO4-DRI. The free-acid by-product of Melanotan-II has the formula of PT-141 (C50H68N14O10), and the two masses are 0.98 Da apart, inside the ±0.1% low-resolution window of about ±1.02 Da at that size, so only the HPLC retention time separates them. SNAP-8 is left out of the mass columns because its listed formula and its registry formula differ (see registry discrepancies); a Met-3 sulfoxide would still sit 15.99 Da above the main peak's observed mass.

Report consequence: a mass difference that matches a row above names the likely species, and a 0 Da species can only show up as a separate or shoulder peak on the chromatogram. The mass spectrometry identity guide covers tolerances and deletion masses, and the expected mass table gives the protonated ions for each compound.

Who performs each stage, and where does Pepta Labs sit?

A peptide manufacturer synthesizes, purifies, freeze-dries and fills the material; a peptide vendor, also called a reseller or supplier, buys finished material and sells it on. Some companies do both, and a vendor's terms or quality page states which role it holds. For Pepta Labs listings the roles divide as follows.

Pepta Labs describes its testing in these words: "Independent third-party HPLC purity analysis and mass-spectrometry identity confirmation, commissioned through the purchasing group on a sampled production run from the source. Pepta Labs does not test in-house." "Because testing is commissioned by the purchasing group, the client field may name the group or source rather than Pepta Labs, and supplier-identifying fields are redacted." The quality page sets out the arrangement in full, and the price per mg page sets the listings side by side by vial size.

Frequently asked questions

How are research peptides made?

Research peptides are made by solid-phase peptide synthesis: protected amino acids are coupled one at a time to a chain anchored on resin, the chain is cut free and deprotected with trifluoroacetic acid, purified by preparative reversed-phase HPLC, often exchanged to the acetate salt, then freeze-dried, filled into vials and sealed.

In what form are research peptides supplied?

As a freeze-dried (lyophilized) solid in a sealed glass vial: the peptide as a salt with its counter-ion, usually trifluoroacetate or acetate, together with residual bound water. Pepta Labs labels state a supplier-stated nominal quantity in mg and carry no lot or batch number.

Why do many synthetic peptides contain trifluoroacetate?

Because trifluoroacetic acid is the main reagent at cleavage (about 95%) and the usual ion-pairing additive in preparative HPLC (about 0.1%), every basic site on the peptide pairs with a trifluoroacetate anion of 113.02 g/mol, and that anion stays in the solid after freeze-drying unless the manufacturer exchanges it for acetate or chloride.

What is the difference between a peptide manufacturer and a peptide vendor?

A manufacturer synthesizes, purifies, freeze-dries and fills the peptide; a vendor or reseller buys finished material and sells it on. The analytical report for a vendor's listing may come from the manufacturer, from an independent laboratory or from neither, so the report's client and laboratory fields are worth reading.

Is Pepta Labs a manufacturer or a reseller?

A reseller. Pepta Labs LLC is a United States-based online reseller of lyophilized research peptides, not a manufacturer, production facility or testing laboratory. It sources through a cooperative purchasing arrangement in which multiple buyers combine volume orders placed directly with manufacturers and fund independent third-party testing on the resulting production runs.

Can mass spectrometry separate a D-residue epimer from the listed peptide?

No. An epimer has the same formula and the same mass as the listed peptide, a difference of 0 Da, so a mass spectrum cannot tell them apart; only chromatography, as a separate or shoulder peak, or a chiral amino-acid analysis can. Six listed compounds carry designed D-residues: FOXO4-DRI, Ipamorelin, SS-31, Melanotan-I, Melanotan-II and PT-141.

All products are supplied for laboratory research use only and are not for human or animal use.